Mallinckrodt Pharmaceuticals (NYSE:MNK) said today that its StrataGraft regenerative skin tissue won regenerative medicine advanced therapy status from the FDA.
The tissue-based therapy is among the first products to be granted the designation. The 21st Century Cures Act, which was passed in 2016, enabled the FDA to give accelerated review approval to products that meet RMAT criteria.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA grants regenerative medicine advanced therapy status to Mallinckrodt’s StrataGraft appeared first on MassDevice.